Zydus Lifesciences Limited · NSE:ZYDUSLIFE
Zydus Lifesciences — Q1 FY25 Earnings Presentation
16 slides from Zydus Lifesciences's earnings presentation, Aug 9, 2024
Slide 1: Exchange filing cover letter: Investor Presentation
August 9, 2024 Listing Department Code: 532321 BSE LIMITED P J Towers, Dalal Street, Mumbai–400 001 Listing Department Code: ZYDUSLIFE NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, C/1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai–400 051 Re: Investor Presentation Dear Sir, Please fi
Slide 2: Zydus Lifesciences Limited Earnings Presentation: Q1 FY25
zyd us Dedicated To Life Zydus Lifesciences Limited Earnings Presentation: Q1 FY25 9th August, 2024 1
Slide 3: Disclaimer and Safe Harbor Statement
Disclaimer and Safe Harbor Statement zyd~ Dedicated To Life • THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF ZYDUS LIFESCIENCES LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES (TOGETHER, THE “COMPANY”). The material that follows is a
Slide 4: Q1 FY25: At a Glance
Q1 FY25: At a Glance Revenues from Highlights of Q1 FY25 R&D Operations ❑ Total revenues grew 21% YoY, led by growth across businesses. Rs. 62,075 mn Rs. 3,925 mn ❑ India branded formulations business posted double-digit growth and 21% YoY 6.3% of revenues outpaced the market growth both in the chro
Slide 5: Key Financial Metrics (1/2)
Key Financial Metrics (1/2) Total Revenues (Rs. mn) Gross Profit (Rs. mn) and Gross Margin % 67.4% 66.3% 67.4% 70.9% 74.4% 62,075 55,338 46,212 51,396 39,223 43,688 45,052 34,652 28,950 30,367 Q1 FY24 Q2 FY24 Q3 FY24 Q4 FY24 Q1 FY25 Q1 FY24 Q2 FY24 Q3 FY24 Q4 FY24 Q1 FY25 Total R&D (Rs. mn) and % to
Slide 6: Key Financial Metrics (2/2)
Key Financial Metrics (2/2) PAT ex. Exceptional (Rs. mn) Organic Capex (Rs. mn) 14,199 3,014 11,823 11,011 2,203 2,162 2,137 2,126 8,007 7,896 Q1 FY24 Q2 FY24 Q3 FY24 Q4 FY24 Q1 FY25 Q1 FY24 Q2 FY24 Q3 FY24 Q4 FY24 Q1 FY25 Net Cash (Rs. mn) Net Working Capital* (Rs. mn) 18,922 71,427 63,906 65,354 1
Slide 7: India Formulations business
India Formulations business Outperformed market growth on the back of strong volume uptake Highlights for the quarter India Formulations Sales (Rs. mn) Q1 FY25 Revenue ▪ Branded business grew faster than the market with Contribution 13% YoY growth. 14,273 13,806 13,758 13,341 12,270 Pillar brands an
Slide 8: Consumer Wellness
Consumer Wellness Strong volume uptake resulted in industry leading growth Highlights for the quarter Consumer Wellness Sales (Rs. mn) Q1 FY25 Revenue Contribution 8,366 ▪ Growth was broad based and largely driven by 17% 7,755 6,936 volume growth. 4,352 3,974 ▪ Personal care segment continued to del
Slide 9: US Formulations business
US Formulations business New launches and base business volume expansion led to strong Highlights for the quarter growth US Formulations Sales (Rs. mn) Q1 FY25 Revenue Contribution ▪ Launched 7 new products. 30,929 24,541 25,235 New launches include the second 505(b)(2) product 18,648 18,427 viz. Zi
Slide 10: International Markets Formulations business
International Markets Formulations business Healthy demand led growth across key markets Highlights for the quarter International Markets Formulations Sales (Rs. mn) Q1 FY25 Revenue Contribution ▪ Robust demand across key markets despite ongoing 5,309 4,893 4,937 4,960 political and economic challen
Slide 11: Updates on Innovation
Updates on Innovation NCE: Saroglitazar Magnesium • Completed patient recruitment for Phase II(b)/ III clinical trials for PBC indication and Phase II(b) clinical trials for Metabolic Dysfunction-Associated Steatohepatitis (MASH) indication for the US market. NCE: Usnoflast • Completed patient recru
Slide 12: ESG Initiatives: Following a holistic philosophy of sustainability
ESG Initiatives: Following a holistic philosophy of sustainability Overview of ESG initiatives undertaken across different areas ESG performance (FY24 vs. FY23) Environment Governance GHG intensity 3% Energy intensity 2% • On-site solar power generation; increase in • Zero tolerance for ethical & in
Slide 13: Zydus at a Glance
Zydus at a Glance ~$2.35 bn Global Revenues1 5th Largest generic Co. in US in terms of prescription3 8 R&D Centers For NCE, APIs, Generics, Vaccines Biosimilars and Wellness products Among 1st Revenues from India Approved product for >35% Geography (Formulations Top 3 In ~55% of product NASH in Indi
Slide 14: Consolidated Financial Performance (reported)
Consolidated Financial Performance (reported) Q1 Q1 YoY Q4 QoQ Rs. mn FY25 FY24 gr. FY24 gr. Total Income from Ops. 62,075 51,396 20.8% 55,338 12.2% Gross Contribution (GC) 46,214 34,652 33.4% 39,223 17.8% Gross Margin % 74.4% 67.4% 70.9% Employee benefits expenses * 7,820 6,524 19.9% 7,545 3.6% R&D
Slide 15: Details of Exchange Rate Fluctuations
Details of Exchange Rate Fluctuations Q1 Q1 YoY Rs. mn FY25 FY24 gr. % A. On operating transactions (above EBITDA line) 233 274 -15.0% a. Included in COGS -19 3 -703% b. Part of other operating expenses (shown separately) 252 271 -7% B. On foreign currency borrowings (part of finance cost) 4 -100.0%
Slide 16: Thank you
Thank you For any queries, please contact Arvind Bothra Arvind.Bothra@zyduslife.com +91-22-62711905 For more information, please visit: www.zyduslife.com Registered Office: www.linkedin.com/company/zyduslife Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi C